Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
51 hedge funds and large institutions have $90.2M invested in Cidara Therapeutics in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 7 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
7% more capital invested
Capital invested by funds: $84.2M → $90.2M (+$5.99M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 55 → 51 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.97M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$303K |
| 3 |
Renaissance Technologies
New York
|
+$193K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$154K |
| 5 |
State Street
Boston,
Massachusetts
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.24M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$443K |
| 3 |
PA
Perceptive Advisors
New York
|
-$225K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$217K |
| 5 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$162K |
CDTX Hedge Fund Activity: Q3 2016 in Review
51 of the 3,758 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2016, worth a combined $90.2M — up 7.1% from $84.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CDTX and 3 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 18 added.
The largest buyer was Sabby Management, adding an estimated $1.97M. The largest seller was RA Capital Management, exiting entirely with an estimated $4.24M sold.
- 51 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2016, down from 55 in Q2 2016.
- Funds reported $90.2M of Cidara Therapeutics stock for Q3 2016, up 7.1% quarter-over-quarter.
- 3 funds opened new Cidara Therapeutics positions in Q3 2016 and 7 closed out, a net change of -4 holders.
- The largest Cidara Therapeutics buyer in Q3 2016 was Sabby Management, an estimated $1.97M added.
- The largest Cidara Therapeutics seller in Q3 2016 was RA Capital Management, an estimated $4.24M sold.
Based on aggregated 13F filings for Q3 2016.